The United States Congress has approved $315 million in new federal funding for research into amyotrophic lateral sclerosis (ALS), marking the highest level of government investment in this area to date. The decision coincides with Rare Disease Month, highlighting the ongoing need for research into conditions that affect smaller patient populations. ALS currently impacts about 30,000 to 31,000 people across the country.
ALS is a rapidly progressing and fatal neurodegenerative disease that attacks motor neurons controlling voluntary muscles, while cognitive abilities remain unaffected. According to Dr. Olga Uspenskaya, Chief Medical Officer at VectorY Therapeutics, the disease’s complex biology and late diagnosis often lead to irreversible neural damage and make treatment challenging.
“If you can slow or halt ALS even modestly, you’re not just changing a market, you’re changing the trajectory of life for almost every ALS patient,” Uspenskaya said.
Indu Navar, CEO and founder of the Peter Cohen Foundation—operating as EverythingALS—shared her personal experience with delayed diagnosis after her husband’s struggle with ALS. The foundation uses technology and data science to connect patients, caregivers, researchers, and drug companies through an open-data platform aimed at improving care and advancing cures.
Navar emphasized the importance of partnerships between organizations like EverythingALS and pharmaceutical companies such as VectorY Therapeutics. “We need to be very open about what we are going through so we can actually fix it,” she said. She explained that collaborations help address development barriers such as strict clinical trial inclusion criteria that might exclude some patients.
EverythingALS includes nearly two dozen pharmaceutical partners in its consortiums. These groups hold regular virtual meetings with patients and researchers, culminating in an annual event where they coordinate their research agendas for the coming year.
The organization is also working toward FDA approval for using detailed speech metrics as clinical trial outcomes to link speech improvements directly to meaningful results for patients. In addition, EverythingALS has launched a monthly expert discussion series called HopeUntangled with ALSUntangled. This initiative reviews alternative and off-label treatments from a scientific perspective to help guide patients on evidence-based medical options.
VectorY Therapeutics is focusing its research on TDP-43 proteinopathy—a common pathological feature affecting up to 97% of ALS patients—which disrupts essential cellular processes linked to neuron degeneration. The company recently began dosing participants in its Phase I/II PIONEER-ALS trial evaluating VTx-002, a vectorized antibody designed to target TDP-43 pathology in people with ALS.
A September 2025 report by BioSpace noted renewed activity in ALS therapy development following setbacks from failed trials and withdrawn drugs.
Uspenskaya expressed optimism regarding future advances: “Advances in genetics, biomarkers and multiomic technologies have revealed that additional factors influence ALS-onset phenotypes and progression rates and patterns.” She added that this growing understanding supports earlier detection efforts, biomarker-guided trials tailored by genetics, and more targeted therapies addressing specific molecular drivers of ALS.
Further discussion on these developments will be available on Thursday’s Denatured podcast episode.
